Johnson & Johnson stock heads into the open after a modest pullback
Published on 09/10/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock closed at USD 268.70 on the NYSE on September 9, 2026, slipping 0.16% from the prior close of USD 269.12 and staying close to the upper end of its 52-week range between USD 173.33 and USD 281.07 per Investing.com data. Compared with that move, the Dow Jones Industrial Average lost about 1.2% on September 9, 2026, underscoring that the broader market fell more sharply than Johnson & Johnson shares.
September 9, 2026 in numbers
Johnson & Johnson Inc. (ISIN US4781601046, NYSE: JNJ) saw its shares trade around USD 268.70 on September 9, 2026, after having opened the session near USD 269.04 according to MarketBeat data from the NYSE quote. The closing level left the stock within roughly 4.6% of its 52-week high of about USD 281.07, while still more than 55% above the 52-week low of approximately USD 173.33 as reflected in the Investing.com overview. In contrast, the Dow Jones Industrial Average declined about 1.2% on September 9, 2026, with the S&P 500 down roughly 0.6%, so Johnson & Johnson outperformed the main US equity benchmarks on a day of broader market weakness.
Trading in Johnson & Johnson on September 9, 2026 unfolded against a backdrop of market pressure from rising energy costs and losses in some pharmaceutical names, factors that weighed more heavily on the blue-chip Dow index than on Johnson & Johnson itself, as summarized by a US closing index wrap on X. On the company side, Johnson & Johnson also featured at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, with management discussing the pace of its medtech business reset, a theme highlighted by Investing.com. The steady positioning near the top of the 52-week range and relative resilience versus the indices suggest that investors treated the shares as a defensive holding amid the latest bout of market volatility.
Conference focus today
Today, September 10, 2026, attention around Johnson & Johnson centers on follow-up from its appearance at the Wells Fargo 21st Annual Healthcare Conference, where management presented on September 9, 2026 at 11:00 a.m. Eastern Time, as detailed by Seeking Alpha. The discussion of the company’s medtech strategy and portfolio, highlighted again by Investing.com, remains a key narrative for investors heading into the US open, especially after the modest decline in the last session and the wider retreat in the major indices.
